asthma
exacerb
often
occur
due
infecti
trigger
determin
whether
infect
present
whether
bacteri
viral
remain
clinic
challeng
diagnost
strategi
clarifi
uncertainti
could
enabl
person
asthma
treatment
mitig
antibiot
overus
explor
perform
valid
peripher
blood
gene
express
signatur
discrimin
bacteri
viral
noninfecti
trigger
subject
asthma
exacerb
subject
suspect
asthma
exacerb
variou
etiolog
retrospect
select
peripher
blood
gene
express
analysi
pool
subject
previous
enrol
emerg
depart
acut
respiratori
ill
rtpcr
quantifi
gene
target
select
microarraybas
studi
follow
logist
regress
model
defin
bacteri
viral
noninfecti
class
modelpredict
class
compar
clinic
adjud
procalcitonin
subject
enrol
clinic
adjud
bacteri
viral
noninfecti
model
predict
congruent
clinic
adjud
viral
noninfecti
case
bacteri
case
none
adjud
bacteri
case
confirmatori
microbiolog
precis
etiolog
group
uncertain
procalcitonin
classifi
one
subject
cohort
bacteri
subject
receiv
antibiot
asthma
exacerb
respons
estim
million
emerg
depart
visit
annual
unit
state
exacerb
frequent
due
extrins
caus
bacteri
infect
viral
infect
noninfecti
caus
medic
noncompli
environment
exposur
antibiot
standard
care
asthma
exacerb
sever
trial
shown
benefit
use
macrolid
asthma
exacerb
despit
patient
present
emerg
room
patient
hospit
asthma
receiv
antibiot
lead
antibiot
resist
antibioticrel
advers
event
addit
cost
antibacteri
antivir
effect
confirm
bacteri
influenza
infect
respect
often
difficult
identifi
etiolog
point
care
diagnost
test
capabl
identifi
caus
asthma
exacerb
could
help
clinician
optim
treatment
includ
antibiot
therapi
tradit
pathogenbas
approach
limit
includ
sampl
bia
timetoresult
inabl
distinguish
infect
colon
consequ
host
responsebas
diagnost
attract
altern
procalcitonin
biomark
associ
bacteri
infect
alreadi
util
guid
antibiot
use
patient
asthma
exacerb
mix
result
recent
publish
microarrayderiv
gene
express
signatur
peripher
blood
success
distinguish
bacteri
viral
noninfecti
caus
respiratori
ill
overal
accuraci
extern
valid
auc
rang
present
evid
signatur
translat
onto
qpcr
platform
test
subject
present
asthma
exacerb
may
differenti
variou
asthma
trigger
approach
could
person
acut
care
asthmat
mitig
emerg
antibiot
resist
studi
approv
institut
review
board
duke
univers
north
carolina
henri
ford
durham
va
medic
center
accord
institut
feder
regul
regard
human
subject
protect
written
inform
consent
obtain
subject
legal
author
repres
subject
enrol
emerg
depart
duke
univers
medic
center
durham
va
medic
center
henri
ford
hospit
univers
north
carolina
medic
center
part
capsod
communityacquir
pneumonia
sepsi
outcom
diagnost
studi
clinicaltrialsgov
part
capss
communityacquir
pneumonia
sepsi
studi
object
capsod
capss
identifi
subject
suspect
sepsi
collect
clinic
inform
sampl
futur
use
patient
elig
capsod
capss
suspect
acut
respiratori
ill
met
least
two
sir
criteria
subject
also
enrol
duke
durham
va
health
care
system
part
radic
rapid
diagnost
categor
acut
lung
infect
radic
enrol
subject
acut
respiratori
ill
suspect
bacteri
viral
noninfecti
etiolog
object
radic
develop
host
responsebas
diagnost
assay
discrimin
bacteri
viral
infect
enrol
subject
medic
histori
clinic
data
includ
vital
sign
laboratori
valu
radiographi
result
patientreport
symptom
score
record
symptom
assess
includ
nasal
discharg
nasal
congest
sneez
cough
malais
throat
discomfort
feverchil
headach
score
base
jackson
score
use
zero
four
scale
absent
mild
moder
sever
sever
subject
also
report
sick
contact
durat
ill
retrospect
adjud
conduct
emerg
medicin
hospit
medicin
pulmonari
medicin
infecti
diseas
physician
previous
describ
adjud
full
access
subject
medic
record
includ
patient
histori
report
symptom
physic
examin
find
clinic
laboratori
test
radiograph
find
absenc
support
microbiologi
evid
adjud
could
still
make
classif
suspect
bacteri
suspect
viral
infect
clinic
present
consist
etiolog
case
independ
review
two
physician
disagr
consensu
panel
conven
render
final
determin
viral
pcr
test
supplement
clinic
microbiolog
test
subject
sever
platform
use
includ
resplex
version
viral
pcr
multiplex
assay
qiagen
xtag
rvp
fast
version
luminex
nxtag
respiratori
pathogen
panel
luminex
viral
pcr
test
result
provid
adjud
avail
time
treatment
order
appli
gene
expressionbas
classif
model
model
must
first
train
cohort
known
phenotyp
train
cohort
includ
subject
present
respiratori
tract
ill
clinic
adjud
microbiolog
confirm
bacteri
viral
noninfecti
ill
valid
cohort
includ
subject
asthma
exacerb
adjud
bacteri
viral
noninfecti
trigger
fig
train
cohort
valid
cohort
retrospect
select
pool
subject
enrol
capsod
capss
radic
valid
cohort
presenc
asthma
exacerb
determin
adjud
basi
preexist
diagnosi
asthma
electron
medic
record
physic
examin
find
wheez
short
breath
compat
treatment
plan
includ
beta
agonist
steroid
inform
antibiot
oseltamivir
prescript
collect
patientreport
symptom
score
ill
durat
presenc
sick
contact
clinic
find
analyz
determin
statist
signific
differ
bacteri
viral
noninfecti
case
clinic
find
assess
includ
routin
avail
time
clinic
evalu
vital
sign
white
blood
cell
wbc
count
radiographi
score
sneez
nasal
discharg
nasal
congest
averag
obtain
composit
nasal
symptom
similarli
symptom
score
patient
sum
achiev
composit
repres
overal
symptom
sever
continu
variabl
analyz
use
kruskalw
statist
test
binari
variabl
analyz
fisher
exact
statist
test
statist
test
employ
use
r
version
procalcitonin
measur
subject
asthma
exacerb
cohort
serum
sampl
measur
roch
elecsi
analyz
roch
diagnost
minivida
immunoassay
plasma
sampl
measur
use
procalcitonin
sensit
kryptor
thermo
fischer
scientif
valu
assign
patient
bacteri
trigger
asthma
valu
consid
nonbacteri
initi
present
peripher
whole
blood
collect
subject
total
rna
extract
use
paxgen
blood
mirna
kit
qiagen
accord
manufactur
protocol
rna
quantiti
qualiti
assess
nanodrop
spectrophotomet
thermo
scientif
alig
bioanalyz
rna
nano
chip
respect
complementari
dna
librari
gener
total
rna
use
superscript
vilo
mastermix
thermo
scientif
semiquantit
realtim
pcr
perform
taqman
low
densiti
array
tlda
although
tlda
card
accommod
target
custom
quantifi
gene
target
number
maxim
perform
accuraci
complet
list
gene
target
includ
tabl
target
select
prior
microarraybas
studi
iter
process
substitut
poorli
perform
assay
differ
probe
transcript
transcript
highli
correl
origin
due
technic
differ
microarray
qpcr
necessari
deriv
new
predict
model
qpcr
data
new
train
cohort
first
raw
gene
express
result
averag
normal
two
refer
probe
exploratori
data
analysi
reveal
differ
two
sampl
batch
correct
use
empir
bayesian
framework
model
normal
batchcorrect
data
use
fit
logist
regress
model
perform
classif
target
weight
select
use
r
packag
glmnet
specif
use
least
absolut
shrinkag
select
oper
regular
perform
nest
cross
valid
select
paramet
result
three
independ
binari
classifi
bacteri
versu
nonbacteri
viral
versu
nonvir
noninfecti
versu
infecti
combin
singl
decis
model
use
oneversusal
scheme
largest
probabl
determin
class
membership
fixedweight
model
appli
asthma
exacerb
valid
cohort
determin
hostrespons
classif
sinc
asthma
valid
cohort
measur
independ
tlda
experi
includ
technic
replic
train
valid
tlda
experi
evalu
potenti
correct
batch
differ
addit
supervis
analysi
also
perform
dimension
reduct
asthmat
cohort
visual
cluster
differ
group
base
infect
statu
respect
target
specif
cluster
algorithm
util
tdistribut
stochast
neighbor
perplex
paramet
implement
r
packag
rtsne
script
written
r
version
train
cohort
includ
subject
acut
respiratori
ill
bacteri
n
viral
n
noninfecti
etiolog
n
tabl
noninfecti
ill
includ
instead
healthi
control
repres
clinic
relev
popul
diagnost
test
noninfecti
etiolog
also
frequent
caus
asthma
exacerb
justifi
inclus
ethnic
gender
wellbalanc
across
group
viral
group
exhibit
lower
ill
sever
infer
hospit
admiss
rate
viral
vs
bacteri
noninfecti
younger
mean
year
compar
bacteri
year
noninfecti
group
year
independ
valid
cohort
subject
asthma
exacerb
identifi
tabl
subject
clinic
adjud
bacteri
infect
though
none
confirmatori
microbiolog
eighteen
subject
viral
infect
viral
etiolog
identifi
case
influenza
rhinoviru
frequent
identifi
case
twentyon
subject
adjud
noninfecti
asthma
exacerb
etiolog
includ
medic
noncompli
season
allergi
smokingillicit
drug
use
dust
exposur
asthma
valid
group
femal
younger
train
cohort
reflect
typic
asthma
demograph
race
sever
ill
similar
across
cohort
first
look
readili
avail
clinic
data
understand
ground
clinic
adjud
determin
whether
clinic
variabl
alon
could
distinguish
group
tabl
puls
oximetri
lower
bacteri
group
mean
vs
viral
noninfecti
p
temperatur
similar
complet
blood
count
cbc
frequent
obtain
bacteri
cohort
case
respect
p
test
mean
wbc
count
higher
bacteri
group
l
l
l
respect
p
wbc
differenti
howev
similar
imag
tend
order
frequent
bacteri
group
imag
studi
radiograph
abnorm
common
bacteri
group
compar
viral
noninfecti
group
respect
p
radiograph
abnorm
includ
bilater
opac
unilater
opac
bronchial
thicken
reticular
mark
adenopathi
nodul
next
determin
whether
patientreport
symptom
score
correl
adjud
fig
clinic
symptom
similar
group
durat
ill
presenc
sick
contact
also
similar
feverchil
p
composit
symptom
score
p
higher
viral
infect
case
bacteri
noninfecti
case
paramet
distinguish
bacteri
noninfecti
group
model
deriv
train
cohort
describ
yield
three
independ
classifi
bacteri
versu
nonbacteri
viral
versu
nonvir
noninfecti
versu
infecti
fig
leaveoneout
cross
valid
within
train
cohort
reveal
accur
discrimin
bacteri
area
receiv
oper
curv
auc
viral
auc
noninfecti
ill
auc
model
creat
train
cohort
fix
appli
case
asthma
exacerb
technic
differ
batch
effect
train
asthma
experi
could
obscur
result
mitig
use
intern
normal
standard
technic
replic
across
experi
strategi
result
excel
correl
experi
r
indic
rtpcr
data
train
valid
cohort
could
directli
compar
use
fixedweight
model
without
need
batch
correct
appli
fixedweight
model
develop
train
cohort
assign
class
bacteri
viral
noninfecti
asthma
case
fig
model
identifi
eight
bacteri
infect
twenti
viral
infect
eighteen
noninfecti
case
proport
similar
clinic
adjud
group
support
fact
viral
noninfecti
trigger
caus
major
asthma
exacerb
howev
differ
gene
express
assign
clinic
adjud
subset
asthma
exacerb
clinic
adjud
bacteri
one
gene
express
signatur
consist
bacteri
infect
instead
classifi
viral
noninfecti
base
gene
express
among
case
adjud
viral
identifi
viral
etiolog
identifi
viral
gene
express
within
noninfecti
cohort
agreement
addit
appli
fix
weight
model
explor
whether
gene
target
could
independ
cluster
subject
infect
statu
use
unsupervis
dimension
reduct
display
close
group
fig
consist
earlier
result
viral
noninfecti
group
separ
well
bacteri
case
form
group
cluster
either
viral
noninfecti
patient
given
discrep
adjud
gene
express
bacteri
case
explor
clinic
featur
discrep
case
two
adjud
bacteri
case
classifi
viral
model
one
patchi
airspac
consolid
xray
clear
xray
enrol
lobar
infiltr
repeat
imag
two
day
later
four
subject
adjud
bacteri
classifi
noninfecti
model
radiograph
abnorm
xray
describ
biapic
opac
atelectasi
versu
pneumon
multilobar
consolid
lobar
infiltr
four
subject
also
leukocytosi
one
elev
neutrophil
percentag
none
bandemia
one
febril
procalcitonin
measur
subject
asthma
cohort
notabl
procalcitonin
avail
adjud
assign
clinic
categori
enabl
use
independ
compar
use
threshold
procalcitonin
classifi
one
subject
bacteri
evid
bacteri
infect
infrequ
popul
interestingli
particular
subject
clinic
adjud
viral
test
posit
rhinoviru
consist
procalcitonin
result
predict
bacteri
gene
express
antibiot
prescrib
case
substanti
higher
percentag
either
adjud
modelpredict
bacteri
infect
fig
fluoroquinolon
macrolid
frequent
prescrib
class
antibiot
usag
subdivid
modelpredict
phenotyp
antibiot
prescrib
frequent
case
viral
noninfecti
signatur
case
bacteri
signatur
support
observ
antibiot
frequent
use
even
bacteri
infect
unlik
clinic
diagnost
criteria
oseltamivir
prescrib
individu
despit
third
test
posit
influenza
rest
neg
virus
clinic
respiratori
viru
test
n
undergo
clinic
respiratori
viru
test
n
rational
oseltamivir
use
case
influenzalik
ill
despit
neg
absent
clinic
test
influenza
notabl
researchbas
supplement
pcr
test
identifi
coronaviru
parainfluenza
two
subject
known
time
clinic
treatment
antibiot
prescript
emerg
room
hospit
stay
record
subject
antibiot
prescript
rate
calcul
clinic
adjud
group
compar
antibiot
prescript
rate
modelpredict
group
respect
percentag
indic
top
bar
antibiot
prescrib
frequent
subject
viral
noninfecti
signatur
subject
bacteri
signatur
http
studi
appli
host
respons
signatur
subject
present
asthma
exacerb
classifi
underli
bacteri
viral
noninfecti
gene
express
pattern
compar
approach
clinic
adjud
procalcitonin
result
indic
peripher
blood
gene
express
profil
may
provid
addit
clinic
use
inform
distinguish
major
class
asthma
exacerb
trigger
acut
care
set
task
challeng
sinc
asthma
exacerb
often
similar
present
exist
diagnost
fail
identifi
underli
caus
result
antibiot
overprescribednearli
half
individu
studi
given
antibiot
despit
hand
adjud
bacteri
infect
impact
antibiot
stewardship
effort
well
patient
outcom
recent
studi
report
longer
admiss
higher
cost
stay
asthmat
treat
antibiot
gene
express
approach
translat
onto
clinic
use
platform
could
help
abat
empir
prescrib
practic
mitig
antibiot
resist
improv
patient
care
studi
first
use
host
gene
express
classifi
identifi
infecti
noninfecti
caus
asthma
exacerb
mani
studi
util
gene
express
profil
better
understand
asthma
pathogenesi
measur
host
respons
use
aid
initi
diagnosi
asthma
stratifi
asthma
sever
drive
immun
respons
identifi
risk
frequent
exacerb
furthermor
studi
character
molecular
respons
asthmat
viral
infect
work
supplement
grow
bodi
research
hope
lead
person
asthma
care
one
challeng
aspect
diagnost
develop
lack
perfect
gold
standardif
clinic
intuit
perfect
would
need
addit
diagnost
test
therefor
discord
clinic
adjud
model
classif
may
arisen
error
either
classif
scheme
discord
classif
involv
bacteri
subgroup
sever
like
explan
seven
individu
clinic
identifi
bacteri
infect
support
microbiolog
therefor
clinic
adjud
assign
base
symptom
physic
examin
laboratori
test
radiographi
poorli
discrimin
bacteri
viral
infect
radiograph
abnorm
import
factor
bacteri
adjud
studi
frequent
present
viral
infect
therefor
subject
adjud
bacteri
classifi
viral
may
true
viral
infect
potenti
reason
observ
discord
bacteri
vs
noninfecti
diagnos
respons
bacteri
noninfecti
inflamm
larg
amount
biolog
overlap
compar
specif
interferon
signal
viral
infect
consist
observ
major
discord
occur
two
group
scenario
fals
neg
bacteri
infect
diagnosi
greatest
concern
due
potenti
miss
opportun
treat
antibiot
iter
model
need
address
rate
fals
neg
bacteri
diagnos
clinic
cost
error
studi
procalcitonin
identifi
one
subject
bacteri
prior
success
procalcitonin
guid
antibiot
use
temper
recent
studi
rais
doubt
one
larg
metaanalysi
estim
sensit
sepsi
anoth
studi
show
sensit
discrimin
bacteri
viral
infect
recent
random
control
trial
show
procalcitoninguid
antibiot
administr
lessen
antibiot
use
due
primarili
concern
bacteri
infect
still
present
contrast
gene
expressionbas
strategi
offer
independ
inform
viral
bacteri
etiolog
may
provid
necessari
reassur
one
limit
studi
sampl
size
attempt
augment
analysi
use
publicli
avail
dataset
howev
avail
asthma
exacerb
cohort
includ
bacteri
viral
noninfecti
etiolog
due
technic
differ
rtpcr
experi
public
domain
microarray
sequenc
fix
weight
model
could
appli
new
model
would
need
train
order
three
phenotyp
must
present
futur
direct
includ
develop
asthma
exacerbationspecif
signatur
larger
prospect
enrol
cohort
could
also
incorpor
clinic
variabl
procalcitonin
model
ideal
cohort
would
support
microbiolog
evid
provid
higher
confid
clinic
adjud
allow
calcul
perform
characterist
addit
enrol
focus
patient
acut
respiratori
ill
suspect
sepsi
focu
exclus
patient
asthma
may
result
bia
compar
dedic
prospect
asthma
studi
addit
uncertainti
preexist
diagnosi
asthma
electron
medic
record
common
dilemma
face
emerg
medicin
clinician
anoth
limit
age
cohort
asthma
exacerb
often
occur
younger
individu
cohort
larg
adult
though
sever
pediatr
subject
includ
howev
signatur
use
studi
previous
evalu
adult
pediatr
patient
show
signific
differ
base
age
nevertheless
assess
perform
younger
subject
asthma
gener
understand
impact
age
genom
measur
host
respons
import
next
step
current
undertak
conclus
host
transcriptom
signatur
may
offer
use
diagnost
inform
aid
manag
patient
asthma
exacerb
confirm
would
requir
larger
cohort
includ
microbiolog
confirm
bacteri
infect
ideal
prospect
random
trial
use
host
gene
express
guid
therapi
rtpcr
platform
describ
studi
requir
sever
hour
sampl
process
time
long
meaning
impact
clinic
applic
howev
translat
gene
express
signatur
onto
clinic
use
platform
current
underway
current
pcrbase
method
yield
timetoresult
approxim
minut
gene
expressionbas
approach
procalcitonin
clinic
intuit
offer
differ
strength
weak
combin
may
best
approach
improv
manag
asthma
exacerb
support
inform
